NCT02117791View on ClinicalTrials.gov

Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )

CompletedOBSERVATIONAL
Enrollment

1,298

Participants

Timeline

Start Date

July 16, 2014

Primary Completion Date

April 3, 2023

Study Completion Date

September 20, 2023

Conditions
Hypertension, Pulmonary
Interventions
DRUG

Riociguat (ADEMPAS, BAY63-2521)

The treatment of Riociguat should comply with the local product information (start dose: 3 mg/day, maximum dose: 7.5 mg/day)

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY